logo
Cough Syrup Recall Sparks Nationwide Warning

Cough Syrup Recall Sparks Nationwide Warning

Newsweek6 hours ago

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Medtech Products Inc. is recalling the Little Remedies brand of Honey Cough Syrup due to fears the product may be contaminated with Bacillus cereus bacterium and concern over the product's shelf-life stability.
Newsweek reached out to the company via email Wednesday for comment.
Why It Matters
Numerous recalls have been initiated in 2025 due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens.
Millions of Americans experience food sensitivities or allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts.
The FDA also warns that people who consume products containing Bacillus cereus may experience nausea, vomiting or stomach cramps from one to six hours after consumption or eight to 16 hours later.
"Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death," the alert warns.
What To Know
In the alert, the FDA says the recalled product was distributed online and to nationwide retailers from December 14, 2022, to June 4, 2025.
The alert has a chart showing UPC numbers with corresponding lot numbers and expiration dates for customers to reference.
The recalled product was packaged in 4-fluid ounce bottles that are amber in color with an outside carton. Pictures of the recalled cough syrup are also in the FDA alert.
The recall does not include other Little Remedies products, the agency says, adding that all lots of the Little Remedies Honey Cough 4-fluid ounce bottles "still within expiry are being included in the scope of the recall."
There have been no "serious adverse events" related to the recall as of Wednesday, according to the FDA.
What People Are Saying
The FDA alert, in part: "Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Complete and submit the report Online: www.fda.gov/medwatch/report.htm
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178."
What Happens Next
Customers who have purchased the recalled cough syrup are advised to stop using the product and consult a medial professional if experiencing adverse reactions, the FDA says.
Those with refund questions may contact the company via email at medicalaffairs@prestigebrands.com, by website at https://www.prestigebrands.com/contactExternal Link Disclaimer or via phone at (800) 754-8853 from 8:30 a.m. to 5:30 p.m. ET weekdays.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gilead's twice-yearly HIV prevention injection gets FDA approval
Gilead's twice-yearly HIV prevention injection gets FDA approval

Yahoo

time2 hours ago

  • Yahoo

Gilead's twice-yearly HIV prevention injection gets FDA approval

The US Food and Drug Administration has approved Gilead's (GILD) new HIV prevention drug. The drug, lenacapavir, only requires an injection every 6 months. Yahoo Finance Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. What's a big milestone for Gilead Sciences today. The Biotech Giant securing FDA approval for its latest HIV treatment. It's a significant step forward for that company and patients. Gilead also seeing a boost on that news. Our senior health reporter Anjali kamlani joins us now. Au, what is what is the big takeaway for for investors watching all this? Yeah, I think the big takeaway here is that investors have actually been waiting for this approval. They anticipate quick uptake and a high volume of uptake of this drug used as a pre-exposure prophylaxis, you know, prep as the common acronym for those types of drugs. Now, Gilead already has discovy for that, but the difference here is that this new use or new approval for Lenca Paviar, it is a twice yearly injectable. And that is the difference between the regular oral and this new approval. And so that is really going to help boost Gilead's revenues for the year. We know that already Lenca Paviar brings in about $60 million for the company, and they're anticipating that that will get boosted to about $150 to $195 million in revenue for the company for the year. That's the estimate that analysts are expecting with the approval, and they've been waiting for this approval for quite some time. So really good news. You can see that, you know, the stock is benefiting from this right now and is supposed to be a game changer for those patients. There are some questions about whether or not being a twice yearly drug, it will be more expensive than say a daily oral. And so that is something that Gilead has tried to addressing that they plan to have a insurance and non-insurance access point for patients as well. Thanks so much for joining us on this. Appreciate it. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know
Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know

Yahoo

time2 hours ago

  • Yahoo

Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know

Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know originally appeared on Parade. From morning coffee to vitamins, there are plenty of must-have's that help set up a successful daily routine. In fact, according to Johns Hopkins Medicine, a whopping 50% of American adults take a multivitamin, vitamin or mineral supplement regularly. If you happen to be part of that group of consistent vitamin takers though, you'll want to double check your medicine cabinet. Because one lot of B12 vitamins is being voluntarily recalled by Vita Warehouse Corp thanks to the potential presence of undeclared peanuts. 🍳 SIGN UP to get delicious recipes, handy kitchen hacks & fun food news in our daily Pop Kitchen newsletter 🍳 Considering these Welby, Berkley Jensen and VitaGlobe vitamins are also sold by some of the most popular retailers like ALDI and Amazon, there's a good chance shoppers may unknowingly have a bottle. According to a company announcement shared by the U.S. Food and Drug Administration, this recall affects one lot of Aldi Welby B12 Energy Support gummies, Berkely Jensen B12 Vitamin gummies and Vitamin B12 Extra Strength gummies. The FDA warns that 'people with an allergy or severe sensitivity to peanuts run the potential risk of serious or life-threatening allergic reactions,' if they take these no illnesses or allergic reactions have been reported so far. The undeclared peanuts were actually discovered by ALDI. After conducting routine testing per its standard protocol, one of the tests 'indicated a potential presence of a peanut allergen.' While internal testing done by Vita Warehouse Corp. 'verified the absence of peanuts," the recall was issued out of caution. So, how do you know for sure if you have one of the affected vitamins? There are a few key ways. First, these were sold nationwide at ALDI and BJ's in-store. They were also sold online on ALDI's, BJ's and VitaGlobe's websites and on Amazon. Additionally, each product will have an expiration date of October 2026. The company says that each of the affected vitamins have the following UPC codes and Lot numbers. Aldi Welby: clear bottle with white cap, using green, red, and white labeling. UPC Code: 4099100290868 Lot #: 248046601* Berkeley Jensen: clear bottle with white cap, using red and pink labeling. UPC Code: 888670132487 Lot #: 248046601* VitaGlobe: clear bottle with white cap, using white and red labeling. UPC Code: 850005214670 Lot #: 248046601* The Lot codes and expiration dates can all be found printed on the bottom of each bottle. The FDA urges consumers who have a peanut allergy to return or throw away any affected vitamins ASAP. Customers who do return them can expect a full refund from the original store of purchase. Those with further questions can contact Vita Warehouse at 1-855-214-0100 Monday through Friday from 7:30 am to 4 pm Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know first appeared on Parade on Jun 18, 2025 This story was originally reported by Parade on Jun 18, 2025, where it first appeared.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store